Search Results
106 hits for »HTA «
The new EU HTA procedure: How can JCAs support access to OMPs for people living with rare diseases Episode 5 – 3 June 2024 (16:00 – 17:00 CET) The new Regulation (EU) 2021/2282 on Health Technology Assessment (HTA) will apply from 12 January 2025, to…
https://www.eucope.org/events/the-new-eu-hta-procedure-how-can-jcas-support-access-to-omps-for-people-living-with-rare-diseases/
…Palma, Senior Director Global Head of Market Access & Access Policy at SOBI, and Alexander Natz, EUCOPE Secretary-General share their views on the EU HTA file, including the recent Council compromise on an HTA proposal. Both experts exchange on the implications for the sector, for…
https://www.eucope.org/sounds-of-science-eucope-podcasts/
…to patients receiving the best medicines possible don’t result in undesirable outcomes. So regulation surrounding research and development of new health interventions like medicines and devices need to be well-integrated, appropriate, and flexible. Similarly, health technology assessments (HTAs) and pricing regimes need to encourage innovation…
https://www.eucope.org/eucope-member-spotlight-qa-with-norgine/
…also taking place with regard to HTA and P&R. This combination of commercial and legislative developments will have long-term implications on ATMPs and the competitiveness of the EU. Suffice it to say, there is a lot happening when it comes to ATMPs, and with the…
https://www.eucope.org/%f0%9f%8e%99%ef%b8%8fsounds-of-science-episode-9-on-atmps/
…EU HTA procedures, and debates the European Health Data Space proposal, it is the opportune moment to update the EU landscape to embrace RWE in the context of ATMPs, building a futureproofed system. Our latest position paper explores the role and acceptability of RWE across…
https://www.eucope.org/position-paper-on-real-world-evidence-rwe-across-lifecycle-of-atmps/
…including a summary of EU HTA regulations, and the EUnetHTA21 collaboration meetings Trends in supranational HTAs other than EUnetHTA – lessons learned Legal framework, the pharma package, how unmet medical need and orphan designation may impact assessment PICOS frameworks and challenges/opportunities in dealing with potentially…
https://www.eucope.org/events/access-2023-europe-annual-meeting-and-expo/
…industry today? We perceive a multitude of uncertainties on the horizon, including political instability, economic fluctuations, financial constraints, heightened competition, the impact of artificial intelligence, and a shortage of human resources. However, the impending European Health Technology Assessment (HTA) procedure stands out as a major…
https://www.eucope.org/eucope-member-spotlight-qa-with-skc-consulting/
LIFE SCIENCE LECTURES – Webinar Series Episode 4 – 14 December 2023 (15:00 – 15:40 CET) Leveraging early advice opportunities in EU HTA On the fourth episode, we discuss how best to navigate early advice opportunities with the new EU health technology assessment (HTA), which…
https://www.eucope.org/events/eucopes-life-science-lectures-episode-four-2/
The new EU HTA requirements: How to prepare for market launch from January 2025 Episode 7 – 17 July 2024 (16:00 – 17:00 CET) In this webinar, EUCOPE experts will provide you with the rundown on the new EU HTA procedure, so that you are…
https://www.eucope.org/events/eucopes-life-science-lectures-episode-seven/
…the EMA and HTA bodies in both pre- and post-marketing contexts; Regulatory streamlining, including reducing approval timelines to bring them in line with global standards; The European Commission must foster an environment that promotes, rewards, and encourages research and development in Europe in the context…
https://www.eucope.org/reinforcing-europe-as-a-centre-for-pharmaceutical-innovation/